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BACKGROUND: Given the high burden of cervical cancer in low-income settings, there is a need for a convenient and affordable
method for detecting and treating pre-cancerous lesions.
METHODS: Samples for comparing the accuracy of cytology, virology and histology were collected. Identification of HPV E6/E7 mRNA
was performed using PreTect HPV-Proofer. HPV DNA detection was performed by GP5þ/6þ PCR, followed by reverse line blot
(RLB) for typing.
RESULTS: A total of 343 women, aged 25–60 years, attending gynaecological polyclinics in DR Congo were included for sample
enrolment. The test positivity rate was conventional and liquid-based cytology (LBC) at cutoff ASCUSþ of 6.9 and 6.6%,
respectively; PreTect HPV-Proofer of 7.3%; and consensus DNA PCR for 14 HR types of 18.5%. Sixteen cases of CIN2þ lesions
were identified. Of these, conventional cytology identified 66.7% with a specificity of 96.2%, LBC identified 73.3% with a specificity of
96.9%, all at cutoff ASCUSþ. HR-HPV DNA detected all CIN2þ cases with a specificity of 85.9%, whereas PreTect HPV-Proofer
gave a sensitivity of 81.3% and a specificity of 96.6%.
CONCLUSION: Both HPV detection assays showed a higher sensitivity for CIN2þ than did cytological methods. Detecting E6/E7
mRNA from only a subset of HR HPVs, as is the case with PreTect HPV-Proofer, resulted in a similar specificity to cytology and a
significantly higher specificity than consensus HR HPV DNA (Po0.0001).
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In African countries, the incidence of cervical cancer is high,
particularly in Sub-Saharan Africa, where cervical cancer is the
most common form of cancer among women (Parkin et al, 1999).
The majority of these countries have not been able to introduce a
cytological screening programme because of the lack of resources
and a sufficiently well-developed infrastructure, besides the fact
that cervical cancer screening unfortunately is one of the many
competing health priorities in these countries.
The incidence of cervical cancer shows a dramatic difference
between high-income and low-income countries. Up to 80% of
women in low-income areas suffer from advanced disease without
possibilities for effective treatment (Goldie et al, 2001)
. Many lives
might be saved by screening for pre-cancerous lesions and
treatment of detected pre-cancers with the appropriate technology.
Different methods for detecting cervical cancer exist: Traditional
morphological methods such as cytology (conventional PAP or
liquid based), naked eye visual inspection using acetic acid or lugol
iodine of the uterine cervix and molecular methods for HPV
detection (Arbyn et al, 2008).
The HPV DNA and mRNA analyses have been introduced on the
basis of the evidence that persistent presence and activity of
oncogenic types of HPV is a necessary prerequisite for the
development of virtually all cervical cancers (Bosch et al, 2002;
Bosch and de Sanjose, 2003; Schiffman et al, 2005b). In general,
HPV infections clear spontaneously. However, continuous expres-
sion of the viral oncogenes E6 and E7 is believed to be a necessary
factor in the progression towards cervical cancer (zur Hausen,
2002).
This study aimed at determining the test accuracy of
colposcopy, conventional cytology and liquid-based cytology
(LBC), in addition to HPV DNA- and mRNA-based assays, for
detecting histologically confirmed cervical intraepithelial neoplasia
grade 2 or worse (CIN2þ) in a mixed population (consisting of
both screening and obstetrical/gynaecological problems), to
determine the most effective screening tool for pre-cancerous
lesions in African countries. The study was set up in a high-risk
urban area in the eastern part of the Democratic Republic of
Congo, which has been affected by civil war and violence against
women for more than a decade.
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complex triage schemes, are preferable, but specificity is then an
indispensable criterion to avoid treating large proportions of the
screened population. In this paper, such a strategy was developed.
A high-risk population was chosen, to guarantee identification
of cases of CIN2þ. Sensitivity and specificity estimates can be
considered as representative for an African female population
consulting gynaecological services; however, positive predictive
values are expected to be inflated because of the relatively high
prevalence of CIN2þ.
MATERIALS AND METHODS
The study was approved by the ‘Regional Committees for Medical
Research Ethics’ in Norway and was performed in accordance with
the ethical standards set by the Declaration of Helsinki 1975,
revised 2000. It was carried out in agreement with the ethical
recommendations of the provincial health authorities in Bukavu
because of the absence of a local ethical committee. All aspects of
the study protocol was thoroughly discussed by Congolese
physicians, co-authors of this paper, who were highly qualified
to evaluate any ethical issues.
Women attending three gynaecological clinics in Bukavu,
Democratic Republic of Congo, during November and December
2003 were recruited for the study.
A health worker informed all women about the study. A printed
consent form translated into the local language was signed by the
participants. Demographic data and information about reproduc-
tive health were obtained. Exclusion criteria were pregnancy,
severe gynaecological bleeding, previous hysterectomy and age
o25 or 460 years. The examination and sampling procedures are
presented in Figure 1. Colposcopy diagnoses were verified by two
physicians by joint examination and consensus. All women with
CIN2 or worse lesions were offered appropriate treatment free of
charge after the histology diagnoses were obtained and transferred
to the physicians in charge of the follow-up of patients.
Training of health professionals involved in sample
collection
Gynaecological examinations were carried out by gynaecologists
and general practitioners, all of whom received intensive training
during a 2-week introduction course given by a Norwegian expert
in low-resource gynaecology and gynaecological oncology.
Collection and transport of samples
PAP smears, PreservCyt vials and histological material were stored
at room temperature and shipped to Norway and Sweden for
preparation and interpretation by well-experienced cytotechnicians
and pathologists.
Histology
Histological material (colposcopically directed or standardised
biopsies at 12 o’clock position and/or endocervical curettage
(ECC)) was obtained from all women for gold standard verification
of the disease status, thereby detecting as many women with
cervical disease as possible and also reducing verification bias.
Biopsy samples and ECC material were immediately transferred
into PreservCyt vials. Histological examinations were carried out
by an experienced pathologist (AKL) at the Norwegian Radium
Hospital (Oslo) according to the WHO classification (Kurman
et al, 1992). In 13 of the cases, more than one sample was taken
from the same woman (one punch biopsy and one ECC or two
punch biopsies). In three other cases, an additional cone biopsy
Result item
Registration Informed consent
Reproductive data and
patient history
Gynaecology examination
Liquid-based cytology
Cervix brush
HPV DNA GP5+/6+ PCR
followed by EIA RLB
HPV mRNA (PreTect HPV-
Proofer/NASBA)
PAP smear cytology
Colposcopy 5% vinegar Colposcopic diagnosis
Biopsy–Directed or
standardised 12 o’clock
or
ECC–In case where the
transformation zone was not
visible
Questionnaire
PAP smear slide
Histopathological
diagnosis
1)
2)
b)
a)
PreservCyt solution
Figure 1 Examination and sampling procedure. The symbols (1) and (2) indicate the order of examinations. The symbols (a) and (b) indicate that the
cervix brush was first used for PAP smear preparation before the brush was submerged into 20ml PreservCyt solution. ECC, endocervical curettage.
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swas obtained to confirm the suspicion of high-grade disease on the
basis of other test results. The score of the highest histology grade
was considered in statistical analysis.
Colposcopy
A colposcopy-directed biopsy sample was taken if any acetowhite
lesion, mosaic, punctation, atypical vessels or other abnormal
lesions were observed. Otherwise, a standardised biopsy sample at
the 12 o’clock position was taken.
Cytology
All conventional PAP smears were examined at the Department of
Cytology at the Norwegian Radium Hospital by one experienced
cytotechnician (BB) and positive smears were reviewed by a
cytopathologist (BR). Slides for LBC were prepared and interpreted
at the Sahlgrenska University Hospital (Gothenburg, Sweden)
using a ThinPrep-3000 processor and an automated slide
preparation unit, producing uniform thin-layer slides. All results
were categorised according to the 2001 version of The Bethesda
System (Solomon et al, 2002).
DNA/RNA isolation from cytological cervical material
Nucleic acids (DNA/RNA) were isolated at NorChip AS (Klokkar-
stua, Norway) using the NucliSENS manual extraction kit
(bioMerieux, Marcy l’Etoile, France) as previously described
(Boom et al, 1990). DNA/RNA was isolated from 5ml of the
20ml PreservCyt vial. The 5ml PreservCyt specimens were
centrifuged for 10min at 2500r.p.m. and the pellets were washed
with 70% ethanol before the addition of 900ml lysis buffer
(NucliSENS, bioMerieux). The extracts were stored at  801C.
HPV RNA analysis by NASBA
For RNA detection, the RNA-based real-time nucleic acid
sequence-based amplification assay (NASBA) was used, focusing
on the reportedly most common oncogenic HPV types 16, 18, 31,
33, 35, 45, 51, 52 and 58 (Clifford et al, 2003a).
(i) HPV type 16, 18, 31, 33 and 45 (PreTect HPV-Proofer) The
HPV mRNA analysis was performed using the NASBA-based assay
PreTect HPV-Proofer (NorChip AS) according to the manufac-
turer’s instructions (a similar product is also marketed under the
brand name NucliSENS EasyQ, bioMerieux).
To avoid false negatives due to degradation of mRNA, primers
and probes against human U1A mRNA are included in the PreTect
HPV-Proofer kit as a performance and integrity control.
(ii) HPV type 35, 51, 52 and 58 Presence of HPV 35, 51, 52 and 58
E6/E7 mRNA was analysed by NASBA using specific primers and
molecular beacons for each HPV type. Artificial oligonucleotides
corresponding to the viral mRNA were used as positive controls
(NorChip AS). Negative controls consisted of Rnase-free water and
were included in each run.
HPV DNA analysis by GP5þ/6þ PCR
The same nucleic acid extracts were used both for the NASBA
assays and for HPV DNA detection by PCR, the latter using the
consensus primer GP5þ/6þ with an enzyme immunoassay
readout as previously described (Jacobs et al, 1997; Snijders
et al, 2005). EIA was performed using two oligoprobe mixtures A
and B. Mixture A contained probes targeting the high-risk or
putative high-risk HPV types 16, 18, 26, 30, 31, 33, 34, 35, 39, 45,
51, 52, 53, 56, 58, 59, 64, 66, 67, 68, 69, 73, 82 (variant MM4) and 82
(variant IS39). Mixture B targeted the low-risk HPV types 6, 11, 32,
40, 42, 43, 44, 54, 55, 57, 61, 70, 71, 72, 81, 83, 84, 85, 86, CP6108
and JC9710. Samples positive for either of the EIA mixtures were
further typed by reverse line blot analysis (RLB). PCR products of
the b-globin gene were included as DNA control.
RLB of GP5þ/6þ PCR products
Reverse line blot typing was performed using a previously
described assay (van den Brule et al, 2002; Snijders et al, 2005)
for detection of 39 HPV types individually (i.e., HPV 6, 11, 16, 18,
26, 30, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57,
58, 59, 61, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82/MM4, 82/IS39 and
CP6108) and of six rare HPV types (i.e., HPV 32, 83, 84, 85, 86 and
JC9710) as a pool.
GP5þ/6þ PCR, EIA and RLB genotyping procedures were
performed at the Department of Pathology, Vrije Universiteit
Medical Center in Amsterdam, the Netherlands.
For the purpose of analysis in this study, we considered the
following 14 HPV types as being of high risk: 16-18-31-33-35-39-
45-51-52-56-58-59-66-68 (IARC, 2007). The other types were
considered as low risk.
In general, all laboratory testing procedures were performed
blindly without knowledge of other test results (except for the joint
colposcopy examination).
Statistical analysis
Test positivity rates and accuracy for underlying CIN2þ were
computed for each of the different methods. McNemar’s w
2-test
was used to study associations between two categorical variables.
Exact binomial confidence intervals (CIs) were computed where
appropriate (Arbyn and Hovland, 2006).
RESULTS
A total of 343 women between 25 and 60 years of age (median: 37
years) were included in this study. The women came from different
locations from the province of South Kivu (Democratic Republic of
Congo).
In Figure 2, some descriptive statistics of the participants are
given. An overview of the different test characteristics of each
assay is presented in Table 1, whereas in Figure 3, sensitivity values
of each test are plotted as a function of the false positivity rate
(1 specificity).
Histology
Altogether, 16 out of 343 women had CIN2þ (eight cases with
CIN3), which translates into a prevalence of 4.7% (95% CI: 2.7–
7.5%). No cancers were diagnosed in the study, most probably
because severe gynaecological bleeding was one of the exclusion
criteria. Histology was unsatisfactory in 30 cases (8.7%), and these
cases were left out of the overall statistical calculations, leaving a
total of 313 cases. Three of the 16 CIN2 or worse lesions were
identified in cone specimens, which were taken because of jointly
positive cytology (HSIL) and nucleic acid assays (HR types) in
spite of benign/low-grade histology in the punch biopsy.
Four of the 16 (25.0%) CIN2 or worse lesions were diagnosed in
women from whom standardised punch biopsy samples were taken
because of the absence of colposcopically suspicious areas.
Colposcopy
In 72 of the 343 (21.0%) women, a colposcopic normal impression
was observed, but colposcopy was regarded as unsatisfactory
because the squamocolumnar junction was not visible.
In 40.9% of women, a positive colposcopic finding was noted,
whereas in 6.3% a CIN2 or more serious lesion was suspected.
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logical outcomes were in 88.9% obtained by sampling with ECC,
the results of which were benign in 79.7% of cases, low grade in
6.3%, high grade in 1.6% and unsatisfactory in 12.5%.
Cytology
Nine PAP (2.6%) and 14 liquid-based smears (4.1%) were assessed
as unsatisfactory. Almost 7% of satisfactory smears were
considered abnormal (ASCUSþ, Table 1): HSIL or worse was
reported in 2.1% of conventional smears and in 2.4% of liquid-
based smears.
HPV DNA in cytological cervical material
The HPV DNA results obtained in the cytological material are
presented in Tables 1 and 2. All samples that were negative by
GP5þ/6þ PCR tested positive by the b-globin DNA control. The
PCR amplification followed by the EIA revealed the presence of
HPV DNA in 104 out of the 343 women (30.3%). In all, 77 of the
104 HPV DNA-positive cases (74.0%) were positive by the EIA
mixture A, which included all high-risk HPV types; 46 of 104
(44.2%) were positive for the EIA mixture B and 19 of 104 (18.3%)
cases were positive for both the A and B mixtures.
When unsatisfactory histology samples (n¼30) were excluded
and the subsequent genotyping data were limited to the 14 HR
types or the five HR types targeted by the PreTect HPV-Proofer,
the positivity rate was reduced to 58 (18.5%) or 28 cases (8.9%),
respectively.
Out of 58 HR HPV DNA-positive samples, the most frequent
type was HPV 35, followed by HPV 45. HPV 16 took the third rank.
A single infection was observed in 62.1% of HPV DNA-positive
women, whereas 24.1% had a double infection and 13.8% carried
three or more types.
343 women for
colposcopy, biopsy, PAP, LBC, DNA
and mRNA analysis 
Results from 313 women with
satisfactory gold standard
≥CIN2, N=16
<CIN2, N=297
30 women excluded due to
unsatisfactory gold standard
(histology)
PAP
Diagnosis, N=305
Excluded: N=8
LBC
Diagnosis, N=301
Excluded: N=12
Colposcopy
Diagnosis, N=252
Excluded: N=61
HPV DNA
Diagnosis, N=313
NASBA mRNA
Diagnosis, N=313
Unsatisfactory PAP
1 with ≥CIN2
7 with<CIN2
Unsatisfactory LBC
1 with ≥CIN2
11 with<CIN2
Unsatisfactory
colposcopy
2 with ≥CIN2
59 with<CIN2
Figure 2 Overview of the material.
Table 1 Test characteristics of the assays
Unsatisfactory
samples Accuracy for CIN2+
Test method
Positive
criterion
Test positivity
rate
N (%) D+ D 
True
positive
False
negative
False
positive
True
negative Sensitivity Specificity
Positive
predictive
value
Negative
predictive
value
PAP XASCUS 21/305 (6.9) 1 7 10 5 11 279 0.667 0.962 0.476 0.982
XLSIL 16/305 (5.2) 1 7 9 6 7 283 0.600 0.976 0.563 0.979
XHSIL 6/305 (2.0) 1 7 5 10 1 289 0.333 0.997 0.833 0.967
LBC XASCUS 20/301 (6.6) 1 11 11 4 9 277 0.733 0.969 0.550 0.986
XLSIL 16/301 (5.3) 1 11 9 6 7 279 0.600 0.976 0.563 0.979
XHSIL 7/301 (2.3) 1 11 5 10 2 284 0.333 0.993 0.714 0.966
Colposcopy XAbnormal 103/252 (40.9) 2 59 11 3 92 146 0.786 0.613 0.107 0.980
XHigh-grade 16/252 (6.3) 2 59 4 10 12 226 0.286 0.950 0.250 0.958
HR-HPV DNA (14 types) 1 of 14 types + 58/313 (18.5) 0 0 16 0 42 255 1.000 0.859 0.276 1.000
NASBA mRNA (9 types) 1 of 9 types + 33/313 (10.5) 0 0 15 1 18 279 0.938 0.939 0.455 0.996
PreTect HPV-Proofer 1 of 5 types + 23/313 (7.3) 0 0 13 3 10 287 0.813 0.966 0.565 0.990
The column ‘Positive criterion’ specifies the different criteria used within each method; ‘Test positivity rate’ gives the number of positive of total number of samples given each
specified criterion for each method; The column ‘Unsatisfactory samples’ specifies number of unsatisfactory samples for each method with a CIN2+ (D+) and without a CIN2+
(D ) diagnosis. Unsatisfactory samples have been excluded from the accuracy calculations for detection of CIN2+.
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different histological diagnoses (n313), 13.9% were found to be
DNA positive in histologically normal cases, 15.8% in HPV/CIN1
lesions and 100% in CIN2 or more serious lesions. Twelve of the 16
(75.0%) CIN2þ cases tested positive for DNA of HPV types 16, 18,
33 and/or 45. Eight of the CIN2þ cases were diagnosed as CIN3
and all were DNA positive, which gave 100% sensitivity and 83.6%
in specificity (accuracy of 84.0%).
The most ideal combinations of HPV types giving maximum
sensitivity and specificity for detection of CIN2þ by using
cocktails targeting increasing numbers of HPV types are shown
in Table 2. Ranking was carried out by increasing each step with
the type that yielded the highest increase in sensitivity and when
the increase in sensitivity was the same for two or more types, the
one that resulted in the lowest loss in specificity was chosen. When
the increase in sensitivity and loss in specificity were equal for two
or more types, the type ranked highest in the list of most prevalent
HPV types in cancer cases as established by Munoz et al (2004)
was chosen.
When we used the same criteria as described above but confined
the analysis to the five types included in the PreTect HPV-Proofer
assay, thereby allowing a direct type-to-type comparison between
the DNA and the mRNA assay, we found a maximum sensitivity
of 75.0% with a specificity of 94.6%.
Sensitivity of HR-HPV DNA detection (i.e., 14 types) for
CIN2þ (100.0%; 95% CI:82.9–100.0%) was significantly higher
than that of both cytology methods, even at cutoff ASCUSþ
(PAP: 66.7%; 95% CI:38.4–88.2%; P for McNemar’s w
2¼
0.014, LBC: 73.3%; 95% CI:44.9–92.2%; P for McNemar’s
w
2¼0.025). Furthermore, the specificity of the HR-HPV DNA
assay was significantly lower than both cytology methods at
cutoff ASCUSþ for outcome CIN2þ (P for McNemar’s w
2 lower
o0.0001).
HPV mRNA in cytological cervical material
The HPV mRNA results obtained in the cytological material are
presented in Tables 1, 3A and 3B.
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Figure 3 ROC diagram showing the accuracy (%) of all methods.
Table 2 The most ideal combination of HPV DNA types giving maximum sensitivity and specificity for detection of CIN2+ for 14 HR-HPV DNA types
HPV type in assay # types TP FN FP TN Sensitivity Specificity
0 0 0 16 0 297 0.000 1.000
HPV16 1 5 11 3 294 0.313 0.990
HPV16-33 2 8 8 4 293 0.500 0.987
HPV16-33-18 3 11 5 6 291 0.688 0.980
HPV16-33-18-51 4 12 4 6 291 0.750 0.980
HPV16-33-18-51-66 5 13 3 9 288 0.813 0.970
HPV16-33-18-51-66-56 6 14 2 12 285 0.875 0.960
HPV16-33-18-51-66-56-45 7 15 1 19 278 0.938 0.936
HPV16-33-18-51-66-56-45-35 8 16 0 27 270 1.000 0.909
HPV16-33-18-51-66-56-45-35-58 9 16 0 28 269 1.000 0.906
HPV16-33-18-51-66-56-45-35-58-68 10 16 0 29 268 1.000 0.902
HPV16-33-18-51-66-56-45-35-58-68-31 11 16 0 31 266 1.000 0.896
HPV16-33-18-51-66-56-45-35-58-68-31-39 12 16 0 33 264 1.000 0.889
HPV16-33-18-51-66-56-45-35-58-68-31-39-52 13 16 0 37 260 1.000 0.875
HPV16-33-18-51-66-56-45-35-58-68-31-39-52-59 14 16 0 42 255 1.000 0.859
Abbreviations: TP¼true positive; FN¼false negative; FP¼false positive; TN¼true negative.
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HPV-Proofer yielded a positive result in 26 cases (7.6%). The most
frequently detected HPV mRNA type was 45, followed by HPV 18
and HPV 16. Thirteen of 16 (81.3% sensitivity) biopsy samples
confirmed to be CIN 2þ were positive for one of the five types
presented in the PreTect HPV-Proofer assay. E6/E7 mRNA of one
or more of four additional types, HPV 35, 51, 52 and 58, was found
in 11 cases. Seven of the eight CIN3 cases were mRNA positive for
one of the five types presented in the PreTect HPV-Proofer assay,
which gave a sensitivity of 87.5 and 94.8% in specificity (accuracy
of 94.6%). The last CIN3 case was DNA 66 positive.
We found 3.7% PreTect HPV-Proofer positives in women
without CIN, no positives in CIN1 and 81.3% in CIN2þ. The
most ideal combinations of HPV types detected by NASBA giving
maximum sensitivity and specificity (with the nine types) for
detection of CIN2þ are shown in Table 3A. Table 3B presents the
five types included in the PreTect HPV-Proofer assay.
Concordance between HPV DNA and mRNA methods
Among samples that were both HPV mRNA and DNA positive,
a 73.0% concordance in typing results was obtained when the
criterion was full identity of all detected types including multiple
infections. In 10 cases, we observed a discrepancy between one or
more HPV types (Table 4) and because of lack of sample material,
these cases could not be re-analysed to resolve typing differences.
Compatible results between HPV mRNA and DNA tests
(meaning at least one common type in a given sample between
these tests) were found for 83.8% of the positive cases.
Figure 3 gives an overview of the accuracy of each of the
methods in percentage, presented in an ROC diagram.
DISCUSSION
In this study, cervical samples from 343 women have been
investigated in a low-income setting by different cytological and
HPV molecular methods to give an overview over test character-
istics and to seek an alternative to cytology. To our knowledge, this
is the first study performed in Africa that has included HPV mRNA
analyses and that involved full gold standard information. As all
samples were tested with all methods including histology, this may
also be one of the rare studies related to cervical pre-cancerous
stages without the need for correction of verification bias.
The prevalence of CIN2þ (4.7%) was high but not exceptional
compared with other African settings in the same geographical
area: 5.3% in Kinshasa (DR Congo) and 5.6% in Brazzaville (R
Congo) (Sangwa-Lugoma et al, 2006; Arbyn et al, 2008).
Four of the 16 (25.0%) CIN 2þ cases were diagnosed by taking
punch biopsy samples standardised at the 12 o’clock position,
which are in accordance with previous results (Sellors et al, 2005;
Jeronimo and Schiffman, 2006). The high PPV in this study should
be explained as the consequence of the high-risk population that
participated in the study and the sensitive verification process
involving biopsy taking even in the absence of colposcopically
suspicious areas. The inaccuracy of colposcopy was evident, most
likely on the basis of only a single biopsy taken in most cases (Gage
et al, 2006) and not merely because of a 2-week introduction
course. The unsatisfactory rate for colposcopy was high (21%). A
reasonable explanation based on age or other factors was not
found.
By both PAP and LBC, a high proportion of histologically
confirmed CIN2þ lesions were diagnosed as normal or low grade
(10 of 16).
The DNA assay (Table 2), focusing on the 14 HR types, HPV 16
showed the highest prevalence for CIN2þ with a sensitivity of
31.3% and a specificity of 99.0%. The second most prevalent HPV
type in CIN2þ was HPV 33. A combination of HPV 16 and 33
Table 3 The most ideal combination of HPV mRNA types giving maximum sensitivity and specificity for detection of CIN2+, for the NASBA mRNA
types (A) and the PreTect HPV-Proofer types, respectively (B)
HPV type in assay # types TP FN FP TN Sensitivity Specificity
(A) NASBA mRNA (nine types)
0 0 0 16 0 297 0.000 1.000
RNA16 1 5 11 0 297 0.313 1.000
RNA16-18 2 9 7 3 294 0.563 0.990
RNA16-18-33 3 12 4 3 294 0.750 0.990
RNA16-18-33-35 4 13 3 5 292 0.813 0.983
RNA16-18-33-35-51 5 14 2 7 290 0.875 0.976
RNA16-18-33-35-51-45 6 15 1 14 283 0.938 0.953
RNA16-18-33-35-51-45-31 7 15 1 14 283 0.938 0.953
RNA16-18-33-35-51-45-31-52 8 15 1 15 282 0.938 0.949
RNA16-18-33-35-51-45-31-52-58 9 15 1 18 279 0.938 0.939
(B) PreTect HPV-Proofer (five types)
0 0 0 16 0 297 0.000 1.000
RNA16 1 5 11 0 297 0.313 1.000
RNA16-18 2 9 7 3 294 0.563 0.990
RNA16-18-33 3 12 4 3 294 0.750 0.990
RNA16-18-33-45 4 13 3 10 287 0.813 0.966
RNA16-18-33-45-31 5 13 3 10 287 0.813 0.966
Abbreviations: TP¼true positive; FN¼false negative; FP¼false positive; TN¼true negative.
Table 4 Discrepancy between DNA and mRNA testing
Case Histological end point DNA result RNA result
1 XCIN2+ 56 18
2 XCIN2+ 16-30-35 16-18
3 XCIN2+ 33-56 33-45
4 oCIN2+ 72 18
5 oCIN2+ 59 45
6 oCIN2+ 31-82 51
7 oCIN2+ 52 51-52
8 oCIN2+ 31-66-42 31-58
9 oCIN2+ X (HR-EIA) 58
10 oCIN2+ 35 58
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Hundred percent sensitivity could be achieved by including an
octet of HPV16-33-18-51-66-56-45-35. Adding more types resulted
in an increasing loss of specificity, as shown earlier by Schiffman
et al (2005a).
An assay with 14 high-risk types yielded a specificity of 85.9%,
which is relatively low compared with, for example, cytology that
reached a specificity of 96.2%. A cocktail of HPV16-18-31-33 and
45 (similar to PreTect HPV-Proofer) in a DNA assay would give a
sensitivity of 75.0% and a specificity of 94.6%. This is lower than
those of PreTect HPV-Proofer assay (81.3 and 96.6%, respectively)
for the same HPV types. On the other hand, DNA analysis with a
different set of five types (i.e., HPV 16-33-18-51-66) yielded similar
sensitivity and specificity values for CIN2þ (81.3 and 97.0%,
respectively) as PreTect HPV-Proofer. The P-value for McNemar’s
w
2 test was 0.32 and 0.16 for differences in sensitivity and
specificity, respectively, between DNA and mRNA testing when
including the same number of HPV types.
For the mRNA-based assay, HPV 16 would also be the first type
to be included (Table 3A) in an ideal assay and this would give
a sensitivity similar to DNA detection and a slightly higher
specificity (100.0 vs 99.0%). The second most prevalent mRNA
HPV type in CIN2þ was HPV 18 and a combination of only HPV
16 and 18 showed a sensitivity of 56.3% and a specificity of 99.0%.
Maximum sensitivity (93.8%) was attained by targeting six types:
HPV 16-18-33-35-51-45, showing a specificity of 95.3%.
PreTect HPV-Proofer showed higher sensitivity for CIN2þ than
for LBC or PAP, considering ASCUSþ as cutoff. Adding four more
HPV mRNA types (HPV 35-51-52-58) resulted in the detection of
two more CIN2þ cases. However, by including these four
additional types, the number of false positives was increased by
eight cases.
Finally, both the the PreTect HPV-Proofer (95% CI: 93.9–98.4 vs
81.4–89.6%; Po0.0001) and the NASBA 9 types (95% CI: 90.6–
96.4 vs 81.4–89.6%; Po0.0001) were significantly more specific for
CIN2þ than for HR-HPV DNA (14 types) detection.
The difference in specificity for detection of CIN2þ using five
HPV mRNA types vs nine HPV mRNA types (96.6 vs 93.9%,
respectively) was not significant. Nevertheless, the 2.5% higher
accuracy obtained by PreTect HPV-Proofer and the favourable
effects of using five types instead of nine types regarding cost and
the follow-up in a low-resource setting give basis to prefer PreTect
HPV-Proofer over a nine mRNA-type assay. The reason for
including additional mRNA types was to determine whether one or
more of these extra types could be particularly prevalent in this
area in which no former HPV epidemiological data exist. The data
did not give reason to believe that this was the case.
Small differences in HPV-type distribution in cervical carcino-
mas exist between different parts of the world. However, in the
meta-analyses performed by Clifford et al (2003b), it is indicated
that the five types, HPV 16, 18, 31, 33 and 45, are the most
predominant HPV types detected in high-grade cervical neoplasia
and comprise almost 97% of the HPV DNA types detected in
cervical carcinomas in Europe and Northern America. The number
is compensated for multiple infections (Clifford et al, 2003b, 2005).
There are also strong indications that the same five types are the
most predominant ones in cervical carcinomas in the rest of the
world (Munoz et al, 2004; Smith et al, 2007). In a previous study,
mRNA transcripts from these five types were detected in 89% of
HPV-positive biopsies of cervical squamous cell carcinomas (88%
by type-specific PCR) (Kraus et al, 2006).
The main problem with HPV DNA testing for all 14 HR types is
the high test-positivity rate, namely, 18.5% in the population
examined in this study.
This translates into twice the test positivity rate compared with
the PreTect HPV-Proofer assay. Despite a very high negative
predicted value of this assay (i.e., very few women negative with
the HR HPV DNA (14 types) test will develop cancer), more than
75% of all HR HPV infections will not persist (Cuschieri et al, 2004,
2005) and therefore do not give rise to CIN2þ, which results in a
rather low PPV compared with, for example, PreTect HPV-Proofer
(26.7 vs 56.5%).
Owing to the fact that a number of CIN2 or worse lesions
spontaneously regress and that the golden standard, histology,
often does not accurately identify the malignant disease, the
‘perfect test’ may therefore actually be located to the left side and
below the 100% mark of sensitivity in the ROC diagram (Figure 3).
The accuracy of PAP was calculated to be just below PreTect
HPV-Proofer and LBC. The HR-HPV DNA-type detection assay
is located quite far from PreTect HPV-Proofer, measured along
the X-axis (1 specificity). In view of the DNA assay, a number of
false positives exceeding the cytology test result accuracy may be
regarded as not feasible for the clinical management system in
low-income countries, where triage options are unavailable. It has
been shown that women who are both positive with HPV DNA and
mRNA are significantly more likely to harbour persistent infection
compared with those in whom only DNA is detected at baseline
(Kraus et al, 2006).
In many settings in low-income countries, there is a need for
robust testing systems with good (but not necessarily the highest
possible) sensitivity and specificity and applicable on the spot
(giving the test result on the same day). A test targeting only the
five most prevalent HPV types in cervical cancer could fulfil this
criterion. In our study, such a five-type DNA test resulted in a
sensitivity of 75.0% and a specificity of 94.6%, using CIN2þ as
threshold for disease. With PreTect HPV-Proofer, the sensitivity
and specificity were 81.3 and 96.6%, respectively. A reasonable
hypothesis is that 18.7% of the CIN2 or worse lesions would have a
low chance of progression. However, the cross-sectional design
does not allow the confirmation of this hypothesis. A combination
of both types of restriction and the fact that PreTect HPV-Proofer
detects mRNA have resulted in a higher accuracy for PreTect
HPV-Proofer compared with HR-HPV DNA. Even if the number of
CIN2þ cases is relatively small in this study, we still see a
contribution to the increasing sensitivity (75.0%–81.3) and
specificity (94.6–96.6%) when including the same five HR HPV
types in an assay performing an mRNA compared with a DNA-
based assay.
The HPV DNA testing in Africa has been suggested by several
experts, as has HPV mRNA testing. However, to date, there is
limited information on the possibilities of using HPV-based tests
in Africa. This study demonstrated for the first time that collection
and storage of mRNA for molecular analysis is feasible in a low-
income setting.
The most realistic way to screen for management of cervical
cancer in low-income settings is by adopting a ‘screen-and-treat’
strategy (Denny et al, 2000, 2005). Therefore, the most desirable
test should detect as few false positives and as many true-positive
pre-cancer and cancer samples as possible (a high specificity in
combination with a high PPV) to minimise both over- and
undertreatment. This will make the test more useful in low-income
countries, where health resources are extremely limited. Detecting
mRNA as opposed to DNA has the potential of giving much more
information about the activity of the oncogenes that are important
for the development of cervical cancer. This in turn can give a
higher clinical specificity, still with the same analytical sensitivity
as PCR. The introduction of mRNA testing with a limited but
area-specific set of HPV types in Africa (and low-income settings
in general) could be a possibility in the near future because of
the development of several sophisticated instruments (e.g., small
battery-operated fluorescense readers) and also because of
improvements in the storage of kit ingredients (e.g., primers
and probes) at room temperature. The results from this study
will be important for investigators in this field to optimise tests
for use in low-income settings in general and in this area in
particular.
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resource areas have been developed. The careHPV test, based on
the hybrid capture 2 (hc2) test (Qiagen, Gaithersburg, MD, USA),
detecting 14 high-risk types, is one of these tests. careHPV is more
feasible for usage in low-resource areas than is hc2; it is less
expensive but is relatively nonspecific (Qiao et al, 2008).
Several companies, including NorChip AS, have developed Lab-
on-a-chip technology (Zhang and Xing, 2007). This technology has
already been adapted for performing hands-free Nucleic Acid
Diagnostic (NAD) (Gulliksen et al, 2005), including complete
extraction of RNA and DNA (Baier et al, 2009). The disposable
chips are designed to include all reagents needed for complete
NAD, including the detection of different mRNA targets, and may
be mass produced to a low cost adapted to a low-resource market.
The PreTect HPV-Proofer technology can be included with a
number of types, adapted specifically for a certain region
according to decisions made by the local health authorities.
Strengths and weaknesses
Sample enrolment was performed strictly according to protocol,
thus providing a high-quality data set and making extrapolations
redundant. The first author was present during all sample
enrolments to assist in any possible way. The collection of a
biopsy sample from each woman reduces verification bias, but
because only a single biopsy sample was taken, bias is not totally
removed. The reason for taking a single biopsy sample was to
minimise the possible discomfort and risk of infection for the
women.
The cross-sectional study design does not allow for the possible
detection of progression of pre-cancerous cases but because of
ethical issues, we could not postpone the treatment, especially as
this study was conducted in a low-resource setting in which
difficulties in recalling the women are usually much higher and
loss in follow-up is expected to be high.
Detectable infections observed during each of the gynaecological
examinations were treated, if possible, free of charge. All women
treated for CIN2 or worse infections were also asked to return to
observe the treatment effect. All mRNA-positive but histology
benign or low-grade women also had an opportunity to return for
follow-up examinations, also free of charge. These results were not
included in the study.
The HPV examination was carried out with a broad spectrum of
methods to identify any possible HPV types. The examination of
conventional PAP smears was performed by laboratories in
Scandinavia and not by additionally including the local pathologist
in the reviewing process because of logistic problems with sending
smears between Scandinavia and Congo.
We cannot confirm HPV epidemiological data from this specific
region, as the number of women included in the study is relatively small.
CONCLUSIONS
This study shows that testing with nucleic acid-based assays is
more sensitive than with either PAP or LBC. Only a few HPV types
are needed in an assay to obtain a good sensitivity while
maintaining a high specificity using CIN2þ as end point.
The combination of over two times higher PPV and a
significantly higher specificity than HR-HPV DNA, in addition to
a substantially higher sensitivity than cytological PAP at cutoff
ASCUSþ (81.3 vs 66.7%), indicates a potential value of PreTect
HPV-Proofer as a diagnostic method in areas without cytology-
based screening possibilities.
In this study, PreTect HPV-Proofer showed a lower sensitivity
for identifying CIN2þ compared with HR-HPV DNA typing with
14 types. Longitudinal studies are necessary to answer whether this
difference in sensitivity is significant in terms of missed cancers.
However, the pooled analyses indicate that the five types included
in PreTect HPV-Proofer cover approximately 90% of HR HPV-
positive cervical cancers worldwide (Munoz et al, 2004).
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